TG THERAPEUTICS
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 264
- Market Cap
- $3.5B
Ublituximab in Combination With TGR-1202 +/- Ibrutinib or Bendamustine in Patients With B-cell Malignancies
Phase 1
Completed
- Conditions
- Chronic Lymphocytic LeukemiaNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2019-11-05
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT02006485
- Locations
- ๐บ๐ธ
TG Therapeutics Investigational Trial Site, Omaha, Nebraska, United States
๐บ๐ธMD Anderson Cancer Center, Houston, Texas, United States
Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies
Phase 1
Completed
- Conditions
- Non-Hodgkin's LymphomaChronic Lymphocytic LeukemiaHodgkin's LymphomaPeripheral T-Cell Lymphoma
- Interventions
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01767766
- Locations
- ๐บ๐ธ
TG Therapeutics Trial Site, Nashville, Tennessee, United States
๐บ๐ธTG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin, United States
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
Phase 1
Terminated
- Conditions
- Non-Hodgkins LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaB-cell LymphomasWaldenstrom's MacroglobulinemiaMarginal Zone LymphomaMantle Cell Lymphoma
- Interventions
- First Posted Date
- 2012-12-07
- Last Posted Date
- 2022-05-11
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01744912
- Locations
- ๐บ๐ธ
TG Therapeutics Investigational Trial Site, Bethesda, Maryland, United States
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- Non-Hodgkins LymphomaB-cell LymphomaWaldenstrom's MacroglobulinemiaMarginal Zone LymphomaChronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Primary Central Nervous System Lymphoma
- Interventions
- First Posted Date
- 2012-07-24
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01647971
- Locations
- ๐บ๐ธ
TG Therapeutics Investigational Trial Site, Memphis, Tennessee, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath